Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections Clinical Trial

Official title:

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04732871
• Other study ID #: 212496
• Secondary ID: 2019-004680-51
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: February 15, 2021
• Est. completion date: May 25, 2026

Study information

• Verified date: December 2023
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 3 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1720
• Est. completion date: May 25, 2026
• Est. primary completion date: June 6, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Male or female participants =60 YOA at first vaccination, who live in the community (CD participants) or in a Long-term care facility (LTCF participants).
• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
• Written or witnessed informed consent obtained from the participant prior to performance of any study specific procedure.
• Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Patients with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable. Exclusion Criteria: Medical conditions
• Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
• Hypersensitivity to latex.
• Serious or unstable chronic illness.
• Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
• Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
• Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
• Any history of dementia or any medical condition that moderately or severely impairs cognition. Prior/Concomitant therapy
• Use of any investigational or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine, or planned use during the study period.
• Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study vaccine administration, with the exception of inactivated, split virion and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study vaccination.
• Previous vaccination with an RSV vaccine.
• Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
• Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine or planned administration during the study period.
• Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine dose or planned administration during the study period. For corticosteroids, this will mean prednisone = 20 mg/day, or equivalent. Inhaled and topical steroids are allowed. Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product. Other exclusions
• History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
• Bedridden participants.
• Planned move during the study period that will prohibit participation in the trial

until the study end. This includes:

• Planned move during the study period to another LTCF that will prohibit participation in the trial until study end.
• Planned move from the community to a LTCF that will prohibit participation in the trial until study end.
• Participation of any study personnel or their immediate dependants, family, or household members.

Related Conditions & MeSH terms

• Respiratory Syncytial Virus Infections

Intervention

Biological:
• RSVPreF3 OA investigational vaccine
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Locations

Country	Name	City	State
Finland	GSK Investigational Site	Espoo
Finland	GSK Investigational Site	Helsinki
Finland	GSK Investigational Site	Helsinki
Finland	GSK Investigational Site	Jarvenpaa
Finland	GSK Investigational Site	Kokkola
Finland	GSK Investigational Site	Oulu
Finland	GSK Investigational Site	Pori
Finland	GSK Investigational Site	Seinajoki
Finland	GSK Investigational Site	Tampere
Finland	GSK Investigational Site	Turku
Germany	GSK Investigational Site	Essen	Nordrhein-Westfalen
Germany	GSK Investigational Site	Essen	Nordrhein-Westfalen
Germany	GSK Investigational Site	Goch	Nordrhein-Westfalen
Germany	GSK Investigational Site	Hamburg
Germany	GSK Investigational Site	Mainz	Rheinland-Pfalz
Germany	GSK Investigational Site	Muenchen	Bayern
Germany	GSK Investigational Site	Wallerfing	Bayern
Germany	GSK Investigational Site	Wuerzburg	Bayern
Japan	GSK Investigational Site	Fukuoka
Japan	GSK Investigational Site	Kumamoto
Japan	GSK Investigational Site	Tokyo
Taiwan	GSK Investigational Site	Changhua
Taiwan	GSK Investigational Site	Taichung
Taiwan	GSK Investigational Site	Taichung
Taiwan	GSK Investigational Site	Taipei
Taiwan	GSK Investigational Site	Taipei
Taiwan	GSK Investigational Site	Taipei
Taiwan	GSK Investigational Site	Taoyuan County
United States	GSK Investigational Site	Coral Gables	Florida
United States	GSK Investigational Site	Evansville	Indiana
United States	GSK Investigational Site	Fort Myers	Florida
United States	GSK Investigational Site	Kansas City	Missouri
United States	GSK Investigational Site	Mobile	Alabama
United States	GSK Investigational Site	Mount Pleasant	South Carolina
United States	GSK Investigational Site	Norfolk	Virginia
United States	GSK Investigational Site	Phoenix	Arizona
United States	GSK Investigational Site	Richfield	Minnesota
United States	GSK Investigational Site	Riverside	California
United States	GSK Investigational Site	Rochester	New York
United States	GSK Investigational Site	San Antonio	Texas
United States	GSK Investigational Site	San Diego	California
United States	GSK Investigational Site	Sarasota	Florida
United States	GSK Investigational Site	Spartanburg	South Carolina
United States	GSK Investigational Site	The Villages	Florida
United States	GSK Investigational Site	Wenatchee	Washington
United States	GSK Investigational Site	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Finland,  Germany,  Japan,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1	RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Day 1
Primary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31	RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.	At Day 31
Primary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6	RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.	At Month 6
Primary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12	RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.	At Month 12
Primary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1	RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.	At Day 1
Primary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31	RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.	At Day 31
Primary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6	RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.	At Month 6
Primary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12	RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.	At Month 12
Secondary	Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1	Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).	At Day 1
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31	Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Day 31
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6	Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 6
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12	Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 12
Secondary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 18	Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 18
Secondary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 24	Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 24
Secondary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 30	Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 30
Secondary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 36	Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 36
Secondary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 13	Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 13
Secondary	Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 25	Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 25
Secondary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 18	Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 18
Secondary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 24	Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 24
Secondary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 30	Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 30
Secondary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 36	Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 36
Secondary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 13	Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 13
Secondary	Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 25	Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).	At Month 25
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 18	Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 18
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 24	Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 24
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 30	Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 30
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 36	Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 36
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 13	Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 13
Secondary	Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 25	Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.	At Month 25
Secondary	Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1	Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Day 1
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Day 1
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Day 31
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Day 31
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 6
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 6
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 12
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12	Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF a and IFN ?, in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 12
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18	Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 18
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18	Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 18
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24	Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 24
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24	Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 24
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30	Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 30
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30	Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 30
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36	Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 36
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36	Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 36
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13	Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 13
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13	Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 13
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25	Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 25
Secondary	CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25	Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF a) and interferon gamma (IFN ?), in vitro upon stimulation with RSVPreF3 peptide preparations.	At Month 25
Secondary	Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1	The solicited administration-site events were erythema, pain and swelling at the injection site.	During the 4-day follow up period after first vaccination (vaccine administered on Day 1)
Secondary	Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 12	Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.	During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Secondary	Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 24	Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.	During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Secondary	Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1	The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius [°C]), headache and myalgia.	During the 4-day follow up period after vaccination (vaccine administered on Day 1)
Secondary	Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 12	Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.	During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Secondary	Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 24	Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.	During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Secondary	Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1	An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	During the 30-day follow up period after vaccination (vaccine administered on Day 1)
Secondary	Number of Participants With Any Unsolicited AEs Following Vaccination at Month 12	Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Secondary	Number of Participants With Any Unsolicited AEs Following Vaccination at Month 24	Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Secondary	Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1	An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.	From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Secondary	Number of Participants With SAEs Following Vaccination at Month 12	Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.	During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Secondary	Number of Participants With SAEs Following Vaccination at Month 24	Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.	During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Secondary	Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1	pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.	From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Secondary	Number of Participants Reporting Any pIMD Following Vaccination at Month 12	Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.	During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Secondary	Number of Participants Reporting Any pIMD Following Vaccination at Month 24	Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.	During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Secondary	Number of Participants With a Fatal SAE, Related SAE and Related pIMDs	A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention.; The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.	From first vaccination (Day 1) up to study end (Month 36)